Roche and Atea had partnered in developing AT-527, an antiviral pill intended to treat nonhospitalized COVID-19 patients. Basel, Switzerland-based Roche will return the rights and licenses for the drug to Boston-based Atea Feb. 10.
Atea will have the full rights to continue clinical development and commercialization of AT-527 worldwide, and it said it intends to move forward with the drug.
“We have the financial resources and the talent to independently drive forward the Phase 3 MORNINGSKY clinical trial program, and we continue to expect data from this trial during the second half of 2022,” Jean-Pierre Sommadossi, PhD, CEO and founder of Atea, said in a news release. “We are energized by the opportunity to move forward with full ownership, providing us with autonomy to efficiently bring AT-527 to market.”
The two drugmakers said last month that the drug failed to benefit nonhospitalized patients in a midstage trial, as was the goal. It didn’t reduce the viral load in patients with mild to moderate symptoms.
But they said the data from the trial suggests AT-527 may be effective in high-risk patients with underlying health conditions.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
